Employment AgreementEmployment Agreement • September 24th, 2010 • BioLineRx Ltd.
This Employment Agreement (this “Agreement”) is entered into on this 24 day of May, 2009 by and between BioLineRx Ltd., a company organized under the laws of the State of Israel, with its offices at 19 Hartum Street, P.O. Box 45158, Jerusalem 91450, Israel (“BioLine”), and Phillip Serlin, I.D. Number 310550157 with an address at 11 Hachazav Street, Bet Shemesh (the “Employee”).
LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • September 24th, 2010 • BioLineRx Ltd. • New York
This Amended and Restated License and Commercialization Agreement (the “Agreement”) is entered into this 26th day of August, 2009, by and among Ikaria Development Subsidiary One LLC, a Delaware limited liability company having a principal place of business at 6 State Route 173, Clinton, NJ 08809, USA (“Ikaria”), BioLineRx Ltd., a corporation organized and existing under the laws of the State of Israel and having a principal place of business at 19 Hartum Street, P.O. Box 45158, Jerusalem 91450, Israel (“BioLineRx Ltd.”), and BioLine Innovations Jerusalem L.P., a limited partnership organized and existing under the laws of the State of Israel and having a principal place of business at 19 Hartum Street, P.O. Box 45158, Jerusalem 91450, Israel (“BioLine Innovations”; together with BioLineRx Ltd., “BioLineRx”).
AMENDMENT AGREEMENTAmendment Agreement • September 24th, 2010 • BioLineRx Ltd.
THIS AMENDMENT AGREEMENT, dated as of the 7th day of March, 2006, (the "Effective Date"), is entered into by and between BioLineRx Ltd. ("BioLine"), Bar-Ilan Research and Development Company Ltd. ("BIRAD") and Ramot at Tel Aviv University Ltd. ("Ramot", and together with BIRAD, the "Licensors").
EARLY DEVELOPMENT PROGRAM AGREEMENTEarly Development Program Agreement • September 24th, 2010 • BioLineRx Ltd.
This Early Development Program Agreement (this “Agreement”) is made as of January 10, 2007, by and between PAN ATLANTIC INVESTMENTS LIMITED, a Barbados company (“Pan Atlantic”) and BIOLINERX LTD., a company organized under the laws of the State of Israel (“BioLine”).
EMPLOYMENT AGREEMENTEmployment Agreement • September 24th, 2010 • BioLineRx Ltd. • Delaware
This Employment Agreement, dated January 2, 2007, is between BioLineRx USA, Inc a Delaware corporation (the “Company”), a wholly-owned subsidiary of BioLineRx, Ltd (“BioLineRx”) and Nir Gamliel an individual residing at 16 Treworthy Road, North Potomac, Maryland 20878 (“Executive”).
AMENDMENT AGREEMENTAmendment Agreement • September 24th, 2010 • BioLineRx Ltd.
THIS AMENDMENT AGREEMENT, dated as of the 20th day of December, 2005, (the “Effective Date”), is entered into by and between BioLineRx Ltd. (“BioLine”), Bar-Ilan Research and Development Company Ltd. (“BIRAD”) and Ramot at Tel Aviv University Ltd. (“Ramot”, and together with BIRAD, the “Licensors”).
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • September 24th, 2010 • BioLineRx Ltd.
This Amendment to Employment Agreement (the “Amendment”), dated as of January 2, 2010 is made between BioLineRx Ltd., which has a place of business at 19 Hartum Street, P.O. Box 45158, Jerusalem 91450, Israel (“BioLine”) and Dr. Kinneret Savitsky with an address at 44 Metudela Street, Tel Aviv 69867 (the “Employee”).
January 8, 2004BioLineRx Ltd. • September 24th, 2010
We would like to congratulate you on your offer to join the BioLineRx family and wish you a fulfilling and productive work experience.
LICENSE AGREEMENTLicense Agreement • September 24th, 2010 • BioLineRx Ltd.
This License Agreement is entered into as of this 10th day of January, 2005 (the "Effective Date"), by and among BioLine Innovations Jerusalem L.P., an Israeli limited partnership, having a place of business at 19 Hartum Street, P.O. Box 45158, Jerusalem , 91450, Israel ("BioLine"); and B.G. Negev Technologies and Applications Ltd., a company formed under the laws of Israel, having a place of business at I Henrietta Szold St., Beer Sheva, 84105 ("BGN") on behalf of Ben Gurion University ("BGU").
AMENDMENT TO THE AMENDED AND RESTATED LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • September 24th, 2010 • BioLineRx Ltd.
This Amendment (this “Amendment”) is entered into this 21st day of April 2010 (the “Amendment Effective Date”) by and between Ikaria Development Subsidiary One LLC, a Delaware limited liability company with a place of business at 6 Route 173, Clinton, NJ, 08809 USA (“Ikaria”), and BiolineRx Ltd., a corporation organized and existing under the laws of the State of Israel and having a principal place of business at 19 Hartum Street, P.O. Box 45158, Jerusalem 91450, Israel (“BioLineRx Ltd.”), and BioLine Innovations Jerusalem L.P., a limited partnership organized and existing under the laws of the State of Israel and having a principal place of business at 19 Hartum Street, P.O. Box 45158 Jerusalem 91450, Israel (“BioLine Innovations”; together with BioLineRx Ltd., “BioLine Rx”) . This Amendment amends the Amended and Restated License and Commercialization Agreement entered into by and between Ikaria and BioLineRx dated as of the 26th day of August 2009 (the “Agreement”). Any defined term
Re: Engagement OfferBioLineRx Ltd. • September 24th, 2010 • Tel-Aviv
By signing this letter you indicate your acceptance of the offer, thus turning this letter into a binding employment contract between you and us (this “Agreement”). For purposes of convenience, BioLine Innovations Jerusalem, L.P. will be called in this letter “BIJ” or “we” and you will be called the “Employee” or “you”.
BioLine Therapeutics Ltd.BioLineRx Ltd. • September 24th, 2010
Further to our discussions, we are pleased to offer you employment with BioLine Therapeutics Ltd., in accordance with the terms and conditions set forth in this letter. By signing this letter you indicate your acceptance to the offer and thus turning this letter into a binding employment contract between you and us (this "Agreement"). For purposes of convenience, BioLine Therapeutics Ltd. will be called in this letter the "Company" or "we", and you will be called the "Employee" or "you".
ContractBioLineRx Ltd. • September 24th, 2010
A Personnel costs Total cost, first year Total cost, 2nd year Total cost, 3rd year Total cost, 4th year Total cost, 5th year Total cost, 6th year Total Budget for 6 years
CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS. ASSIGNMENT AGREEMENTAssignment Agreement • September 24th, 2010 • BioLineRx Ltd.
This Assignment Agreement, dated as of the 2 day of July, 2006 , (the “Effective Date”), is entered into by and between BioLineRx Ltd. (“BioLine”), BioLine Innovations Jerusalem, LP (“BIJ”), Bar-Ilan Research and Development Company Ltd. (“BIRAD”) and Ramot at Tel Aviv University Ltd. (“Ramot”, and together with BIRAD, the “Licensors”).
Bridge Loan AgreementBridge Loan Agreement • September 24th, 2010 • BioLineRx Ltd.
This Bridge Loan Agreement (this "Agreement") is entered into as of January 10, 2007 (the "Effective Date"), by and between BioLineRx Ltd., an Israeli company (the "Company"), and Pan Atlantic Investments Limited, a Barbados company (the "Lender").
October 13, 2004BioLineRx Ltd. • September 24th, 2010
Further to our discussions, this is to set forth in writing our agreements regarding your engagement as the General Manager of a wholly owned subsidiary company which may be established by us as the management company of a biotechnology incubator in Jerusalem which shall be established by us if and when we shall win a tender of the Office of the Israeli Chief Scientist to establish, operate and manage such an incubator. For purposes of this letter agreement, we shall be referred to as "BioLine", the biotechnology incubator shall be referred to as the "Incubator", and the Incubator's management company shall be referred to as the "Management Company".
LICENSE AGREEMENTLicense Agreement • September 24th, 2010 • BioLineRx Ltd.
THIS LICENSE AGREEMENT (the “Agreement”) is entered into as of this 25 day of November, 2007 (the “Effective Date”), by and among BioLine Innovations Jerusalem, LP, a limited partnership formed and existing under the laws of the State of Israel, having a place of business at 19 Hartum Street, P.O. Box 45158, Jerusalem, 91450, Israel (“BioLine”), and Innovative Pharmaceutical Concepts (IPC) Inc., a company formed and existing under the laws of the British Virgin Islands, having a place of business at Geneva Place, 2nd Floor, 333 Waterfront Drive, P.O. Box 3339, Road Town, Tortola, British Virgin Islands (“Licensor”).
RESEARCH AND LICENSE AGREEMENTTeam Agreement • September 24th, 2010 • BioLineRx Ltd.
This License Agreement is entered into as of this 15 day of April, 2004 (the “Effective Date”), by and among BioLineRx Ltd., a company formed under the laws of Israel, having a place of business at 19 Hartum Street, P.O. Box 45158, Jerusalem, 91450, Israel (“BioLine”); Bar-Ilan Research and Development Company Ltd., a company formed under the laws of Israel, having a place of business at Bar-Ilan University, Ramat Gan, 52900 (“BIRAD”); and Ramot at Tel Aviv University Ltd., a company formed under the laws of Israel, having a place of business at Tel Aviv University in Ramat-Aviv, Tel Aviv 61392, Israel (“Ramot”). BIRAD and Ramot shall be referred to together as the “Licensors”.
TRANSLATION FROM HEBREW Unprotected Lease Agreement Made and executed in Jerusalem on the 10th day of July, 2005 BetweenUnprotected Lease Agreement • September 24th, 2010 • BioLineRx Ltd.
Re: First Amendment of Research and License Agreement, Dated April 15, 2004, by and Among BioLineRX Ltd., Ramot at Tel Aviv University, Ltd and Bar-Ilan Research and Development Company Ltd. the "Agreement")BioLineRx Ltd. • September 24th, 2010
You have brought to our attention the fact that Section 9.1.1 of the Agreement (Licensor Confidential Information) has created a problem with respect to your ability to enter into agreements with potential contractors/collaborators and to attract investors. Specifically, the provision states that your obligations of confidentiality and non-use (other than for the purposes of the Agreement) remain in effect during the term of the agreement, and for five (5) years thereafter. As you have explained to us, potential contractors/collaborators are unwilling to be bound by such confidentiality and non-use obligations with respect to the Confidential Information (as defined in the Agreement) for such undefined term. Therefore, in order to enable you to continue to develop Licensed Product (as defined in the Agreement) and to exercise your rights and fulfill your obligations under the Agreement, we hereby agree to amend the agreement as follows, effective immediately:
Amendment and Update of the Unprotected Lease Agreement BetweenUnprotected Lease Agreement • September 24th, 2010 • BioLineRx Ltd.
ASSIGNMENT OF BL-1040 PROJECTAssignment • September 24th, 2010 • BioLineRx Ltd.
THIS ASSIGNMENT (the "Assignment") is made effective as of January 1, 2009, by and between BioLine Innovations Jerusalem, Limited Partnership ("Assignor") and BioLineRx, Ltd. ("Assignee").
